Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Return to V2 Home
Search
ACQUIRED COMPANY
  
My Lists

Genentech  (Stock symbol: DNA ) Acquired by Roche (2009 $ 46,800,000,000 )
1 DNA Way
 South San Francisco, CA 94080
 USA
 (650)-225-1000
Website Company Summary Management Team
Management
CEO: Bill Anderson (1/1/2017)
President/COO/Operations: Leonard Kanavy (10/04/2006)
General Management: Merdad Parsey (2015) ; Sandra J Horning (07/28/2009) ; Ed Tucker (12/31/2013); Hideki Garren ; Jakob Dupont (1/31/2017) ; Morgan Sheng (09/10/2008) ; David W Lair (10/31/2013) ; Kim Branson (4/30/2018) ; Mark Lee (10/31/2017)
Technology: Ronald Cantrell (9/30/2015)
Sales/Marketing: Nathanael Rosidi ; Dawn Barsy
Board
Outside board: (May no longer be on the board) Herbert W Boyer (Genentech) ;  William M Burns (Roche Division CEO) ;  Erich Hunziker (The Roche Group CFO) ;  Jonathan K C Knowles (The Roche Group Division President) ;  Donna L Reed (San Diego Gas & Electric and Southern California Gas Co. President/CEO) ;  Charles Sanders (Glaxo Former CEO/Chairman) ;  Arthur D Levinson (Genentech Former President/CEO)
Former outside board: Tom Perkins (Kleiner Perkins)
Company
Business description: Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Delivering innovative medicines to patients with serious or life-threatening medical conditions is what Genentech is all about. Today, Genentech manufactures and commercializes 10 protein-based products for serious or life-threatening medical conditions -- giving Genentech one of the leading product portfolios in the biotech industry. Our focus is on developing innovative therapies that fill significant unmet medical needs and positively impact the world of human health. Genentech currently manufactures and commercializes 12 products in the United States for a variety of medical conditions, including cancer, heart attack, allergic asthma, psoriasis, stroke, growth hormone deficiency and cystic fibrosis.
Partners include: Abgenix;  Actelion;  Adaptive Biotechnologies ;  Alkermes;  Amgen;  Connetics;  COR Therapeutics;  GenVec;  Glycomed;  ImmunoGen;  Incyte;  InterMune;  Novartis;  Roche;  Seattle Genetics;  SurModics;  Vaxgen (renamed DiaDexus, see DiaDexus);  Xoma;  Aventis SA;  Biogen;  Boehringer Ingelheim;  Cambridge Antibody Technology;  DAKO;  Genetics Institute;  Hanmi;  Human Genome;  IDEC;  Lonza;  Lonza Group ;  Millennium;  OSI;  PharmaciaAndUpjohn;  Schering;  Scios Nova;  Sensus Corporation;  Sumitomo Pharmaceuticals Corp.: ;  Urogenesys
Capital
Ownership: Acquired by Roche (2009 $ 46,800,000,000 )
Stock Symbol: DNA

Last Tweets

 

Last Mentions

Overview
Record updated: Dec 2016
Sector: Biotech
Headcount: 7001-10000 as of May 2008
Ownership: Acquired by Roche (2009 $ 46,800,000,000 )
Stock Symbol: DNA
©2003-2022 Link Silicon Valley LLC Home